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Summary A humanised IgGl/k version of A33 (hA33) has been constructed and expressed with yields up to
700 mg 1' in mouse myeloma NS0 cells in suspension culture. The equilibrium dissociation constant of hA33
(KD= 1.3 nM) was shown to be equivalent to that of the murine antibody in a cell-binding assay. hA33
labelled with yttrium-90 using the macrocyclic chelator 12N4 (DOTA) was shown to localise very effectively to
human colon tumour xenografts in nude mice, with tumour levels increasing as blood concentration fell up to
144 h. A Fab' variant of hA33 with a single hinge thiol group to facilitate chemical cross-linking has also been
constructed and expressed with yields of 500 mg 1-1. Trimaleimide cross-linkers have been used to produce a
trivalent Fab fragment (hA33 TFM) that binds antigen on tumour cells with greater avidity than hA33 IgG.
Cross-linkers incorporating 12N4 or 9N3 macrocycles have been used to produce hA33 TFM labelled stably
and site specifically with yttrium-90 or indium-1Il respectively. These molecules have been used to demon-
strate that hA33 TFM is cleared more rapidly than hA33 IgG from the circulation of animals but does not
lead to accumulation of these metallic radionuclides in the kidney. 9Y-labelled hA33 TFM therefore appears
to be the optimal form of the antibody for radioimmunotherapy of colorectal carcinoma.
Keywords: Radioimmunotherapy; antibody; yttrium; tri-Fab
Tumour localisation and therapy studies have now been per-
formed using a considerable number of antibodies directed to
tumour-associated antigens. These studies have demonstrated
that uptake of radioimmunoconjugates by human solid
tumours is generally very low, rarely exceeding 10% ofinject-
ed dose per kilogram of tumour, and that therapeutic res-
ponses are observed only rarely. Our aim has been to develop
a new generation of radioimmunoconjugates for successful
treatment of solid tumours, and to this end we have attempt-
ed to optimise all aspects of the conjugate - the antibody
targeting moiety, therapeutic effector and linkage between the
two. We have addressed these issues in the construction and
characterisation of novel radioimmunoconjugates for therapy
of colorectal cancer metastases based on the antibody A33.
This antibody recognises a poorly characterised antigen ex-
pressed by virtually all primary and secondary colon cancers.
A33 labelled with '"'I has shown impressive, selective tumour
localisation in patients with hepatic metastases of colorectal
carcinoma (Welt et al., 1990, 1994). A phase I/II study has
been conducted (Welt et al., 1994) with this murine antibody,
in which some tumour responses were observed at the max-
imum tolerated dose (75 mCi m-2). The major limiting tox-
icity was haematological, as observed in almost all therapy
studies with radioimmunoconjugates. All patients treated
developed a human anti-mouse antibody (HAMA) response
after one administration, and this led to very rapid clearance
of the conjugate upon retreatment, consistent with all
previous results with rodent antibodies. These data suggest
that A33 is a promising antibody for successful radioim-
munotherapy of colon cancer, and the purpose of this study
has been to design and develop a second generation reagent
based upon it. The key to the development of successful
radioimmunotherapy will be the identification of reagents
capable of delivering a killing dose to tumour cells without
unacceptable toxicity to normal tissues. To this end we are
evaluating several alternative radioimmunotherapeutic
strategies including the use of isotopes which require inter-
nalisation into the cell for cytotoxicity, such as 125I (which are
less toxic to normal tissues), and engineering the antibody for
the optimal delivery of highly cytotoxic agents such as
90Y.
The radioisotope 9'Y has been used in several radio-
immunotherapy studies and is an attractive isotope for this
purpose owing to its appropriate physical properties. As a
pure high-energy P-emitter 9Y has advantages over the more
commonly used "''I in terms of greater energy deposited and
ease of patient handling. The half-life of 9Y (2.7 days) is
sufficient for tumour localisation and short enough to
minimise toxicity in organs involved in catabolism. Previous
studies with 9'Y have been limited by the use of poor acyclic
chelators such as DTPA which allows leakage of 9'Y from
the chelator under physiological conditions with subsequently
increased bone marrow toxicity (Hnatowich et al., 1988;
Larson, 1991). Attempts to circumvent this problem by the
co-administration of free EDTA to chelate free 9Y released
have also been made but showed only a very limited
improvement (Stewart et al., 1990). Stable macrocyclic chela-
tors for 9'Y have now been developed based on the macro-
cycle 12N4 (also known as DOTA), which essentially com-
pletely prevents loss of the isotope from the conjugate under
physiological conditions (Deshpande et al., 1990; Harrison et
al., 1991; DeNardo et al., 1994).
We have attempted to optimise the antibody part of the
conjugate in two ways: by humanisation to overcome the
HAMA response and by using a trivalent Fab fragment of
the antibody, which has pharmacokinetic properties more
suitable than those of whole antibody for delivering 9'Y. It is
now possible to replace most of the rodent-derived sequences
of an antibody with sequences derived from human
immunoglobulins without loss of antigen-binding activity.
The first generation of humanised antibodies involved the
fusion of the variable domains of the mouse antibody to
human immunoglobulin constant regions to produce chimeric
antibodies. Several such antibodies with specificity for
tumour antigens have been administered to patients (LoBug-
lio et al., 1989; Baker et al., 1991; Saleh et al., 1992). In
general an immune response still develops against these
Correspondence: DJ King
*Present address: Scotgen Biopharmaceuticals, Aberdeen, Scotland
Received 30 May 1995; revised 27 July 1995; accepted 2 August 1995chimeric antibodies in a large proportion of patients,
although the level of the response is usually lower than that
seen with the parent mouse antibody and is directed against
the variable regions. The reduced HAMA response to
chimeric antibodies leads to the expectation that more exten-
sive humanisation, i.e. humanisation of the variable region
outside the antigen-binding site as well as the constant
domain may further diminish the immune response, and
preliminary data with the first few antibodies fully humanised
in this manner are consistent with this view (Caron et al.,
1992; Isaacs et al., 1992; Stephens et al., 1994). Full human-
isation involves redesigning the variable domains so that the
amino acids contributing to the antigen-binding site of the
mouse antibody are integrated into the framework of a
human antibody variable region. Several strategies have been
employed for full antibody humanisation (reviewed in Moun-
tain and Adair, 1992).
We have recently described the evaluation, in a nude
mouse xenograft system, of chemically cross-linked antibody
fragments for radioimmunotherapy when labelled with 9Y
via the 12N4 macrocycle (King et al., 1994). In this study we
demonstrated the potential targeting advantages of a tri-Fab
fragment termed TFM. In this paper we describe the con-
struction, expression and tumour cell binding properties of
humanised variants of the antibody A33, together with
studies on their biodistribution and pharmacokinetics in
animals when labelled with 90Y or "'In. Humanised A33
TFM labelled with 90Y is a promising reagent for therapy of
colorectal carcinoma.
Materials and methods
Cloning and expression ofgenesfor A33, humanised A33 IgGI
andhumanised A33 Fab'
A33 hybridoma cells were cultured in RPMI-1640 medium
supplemented with 10% fetal calf serum and 1 mM gluta-
mine. Total RNA was prepared from 109 hybridoma cells
using guanadinium isothiocyanate and poly(A+) mRNA iso-
lated from this by oligo (dT) affinity chromatography. First
strand cDNA was synthesised from 10 mg of mRNA using
the Amersham International cDNA synthesis kit. DNA
sequences encoding A33 variable domains (including signal
sequences for secretion) were amplified from the cDNA using
the PCR procedure described by Jones and Bendig (1991) but
with primers designed to allow facile cloning of the PCR
products into vectors for expression in mammalian cells.
These vectors were derived initially from pEE6 (Stephens and
Cockett, 1989). Figure 1 shows final NSO expression vectors.
PCR-amplified fragments for the light chain variable domain
were cloned between the BstI and SplI sites of pMRRO10, a
pEE6 derivative constructed to allow expression of such
sequences as kappa chimeric light chains. PCR-amplified
fragments for the A33 heavy chain variable domain were
cloned between the HindIII and ApaI sites of pMRRO1 1, a
pEE6 derivative constructed to allow expression of such
sequences as fy-1 chimeric heavy chains. The cloned variable
region genes were sequenced by the double-strand dideoxy
chain terminating method using T7 DNA polymerase
(Sequenase version 2.0, United States Biochemical, Cleve-
land, OH, USA).
The humanised variable domains were assembled by the
procedure of Daugherty et al. (1991), using primers which
allowed facile cloning into pMRR01O and pMRR011 for the
light and heavy chains respectively. These humanised variable
region genes were sequenced by the same procedures used for
the murine variable region genes. An expression vector for
the hA33 Fab'Acys heavy chain with a single hinge thiol was
constructed by replacing the y-1 constant domains with the
appropriate segment from the cB72.3 Fab'Acys gene des-
cribed by King et al. (1994).
Transient co-expression of murine IgG heavy and light
chains, or humanised IgG and Fab' heavy and light chains
were achieved by co-transfection of the separate expression
A33 and A33 TFM conjugates forradiommunotherapy
DJ King eta/ r
1365
.CiaI
Figure 1 Vectors for the expression of hA33 IgGI and hA33
Fab'Acys in NSO cells.
vectors into CHO-L761h cells as described previously
(Cockett et al., 1990). For stable cell line development the
heavy and light chain expression units were combined in a
single plasmid. This was accomplished by replacing the
NotI-BamHI stuffer fragment in the light chain expression
plasmids with the NotI-BamHI fragments carrying the
hCMV promoter/enhancer and heavy chain genes from the
heavy chain expression plasmids. The final expression plas-
mids were termed pAL71 and pAL72 for hA33 IgGI and
Fab'Acys respectively (Figure 1). Stable NSO cell lines for the
production of hIgGi and hFab' were then established by
transfecting these plasmids according to the procedure of
Bebbington et al. (1992). After transfection the cells were
plated at 2 x 105 cells per 96-well plate in Dulbecco's
modified Eagle medium containing 10% dialysed fetal calf
serum and 2 mM glutamine. After 24 h cells were selected by
the addition of methionine sulphoximine to the medium at a
final concentration of 7ELM. After 21 days of culture, resis-
tant colonies were picked and expanded for analysis of prod-
uctivity. The highest producers were selected for production
of recombinant antibody in roller bottle culture.
Preparation ofhumanised A33 IgG, Fab', DFM and TFM
hIgG was purified from tissue culture supernatants of NSO
cells using protein A-Sepharose affinity chromatography and
characterised by SDS-PAGE as previously described (King
et al., 1992). hA33 Fab'Acys was purified from cell culture
supernatant by chromatography on protein A-Sepharose
using the low affinity protein A binding site on Fab' as a
basis for purification. A column of protein A-Sepharose wasA33 and A33 TFM conjugates for radiommunotherapy
DJ King etal
1366
equilibrated with 100 mM boric acid buffer pH 8.0 containing
150mM sodium chloride. The tissue culture supernatant from
NS0 cells expressing hA33 Fab'Acys was adjusted to pH 8.0
by the addition of 1 M Tris and applied to the column. After
washing with the equilibration buffer the Fab' was eluted
with 0.1 M citric acid, collecting fractions directly into
sufficient 1 M Tris to immediately adjust the pH of the frac-
tion to between 6 and 7.
After dialysis and ultrafiltration hA33 Fab'Acys was cross-
linked to DFM and TFM using the maleimide-based homo-
bifunctional and homotrifunctional linkers CT52 and CT998
respectively, as described for cB72.3 Fab'Acys (King et al.,
1994). These cross-linkers contain the 12N4 macrocycle for
incorporation of 'Y. The DFM and TFM produced were
purified by gel filtration using a Sephacryl S-200HR column
(Pharmacia). Radiolabelling with 'Y was performed as des-
cribed previously (King et al., 1994).
Antigen binding assays
These were performed using cells of two human colorectal
tumour cell lines which express the A33 antigen, Colo2O5 and
SW1222. These cells were cultured in DMEM containing
2 mM glutamine and 10% fetal calf serum (Gibco). Assemb-
led antibody in culture supernatants and in purified prepara-
tions was quantitated in an ELISA (Whittle et al., 1987).
Direct binding of murine and humanised antibodies to
SW1222 cells was measured in a FACScan assay. SW1222
cells were trypsinised to remove them from culture flasks,
washed with phosphate-buffered saline (PBS) and resus-
pended in PBS containing 10% bovine serum and 0.1%
sodium azide. Humanised A33 antibody was serially diluted
in PBS containing 10% FCS and 0.1% sodium azide and
added to 2 x 105 cells. Following a 1 h incubation on ice the
cells were washed in PBS and then incubated with a rhod-
amine anti-(human Fc) conjugate (1:1000 in PBS, 10% FCS
and 0.1% sodium azide) for a further 1 h on ice. After
washing in PBS, the amount of rhodamine-labelled A33
antibody conjugate bound to the cells was measured in a
FACScan analyser (Becton-Dickinson). Direct binding of
murine A33 was measured by FACScan analysis after
incubation of SW1222 cells with FITC-labelled antibody.
Suitable non-specific antibody controls were carried out to
demonstrate that A33 binds specifically via antibody-antigen
interaction rather than non-specifically through Fc interac-
tions.
Determination of affinities of murine and humanised anti-
bodies was based on the procedure described by Krause et al.
(1990). Briefly, antibodies were labelled with fluorescein using
fluorescein isothiocyanate (FITC) titrated from 1.3 mg ml-',
then incubated with 2.8 x 105 SW1222 cells for 2 h on ice in
350pl PBS containing 5% FCS and 0.1% sodium azide. The
amount of fluorescence bound per cell was determined in a
FACScan and calibrated using standard beads (Flow
Cytometry Standards Corporation). The number of
molecules of antibody that had bound per cell at each
antibody concentration was thus established and used to
generate Scatchard plots.
Competition assays were performed by FACScan quantita-
tion of bound FITC-labelled murine A33 after incubating
Colo2O5 cells with a standard quantity of the murine
antibody together with a dilution series of the humanised
variants.
Radiolabelling and animal studies
Antibodies were labelled with 9Y via the macrocyclic ligand
tetra-azocyclododecane tetra-acetic acid, (termed 12N4 or
DOTA) coupled to the immunoglobulin via 12N4-maleimide
linkers (Harrison et al., 1991) as previously described (King
et al., 1994). Radiolabelling of hA33-12N4 conjugates with
9Y and 125I, and biodistribution studies in nude mice bearing
subcutaneous SW1222 tumour xenografts were carried out
also as described (King et al., 1994). Antibodies were labelled
with "'In via a second macrocyclic ligand, 1,4,7-triaza-
cyclononane triacetic acid or 9N3 using 9N3-maleimide
linkers as described previously (Turner et al., 1994).
Biodistribution studies in guinea pigs were carried out after
i.v. administration to male outbred Dunkin-Hartley guinea
pigs (Interfona, Huntingdon, UK) of approximately 250-300
g. Groups of four guinea pigs were injected with each 9Y-
labelled component into the ear vein and sacrificed post
administration at the time intervals indicated. Blood samples
were taken and tissues processed as previously described for
mice (King et al., 1994). Pharmacokinetic studies in cynomol-
gus monkeys of 5-7kg (two per group) were carried out
after i.v. injection of radiolabelled components. Blood sam-
ples were taken at 0.5, 1, 2, 4, 6, 8, 24, 48, 72, 96, 120, 144
and 168 h for counting.
Dose calculations
An exponential, non-linear least-squares fitting procedure
was used to determine the blood clearance parameters for
each monkey. Mean values ofthe blood clearance parameters
for IgG, TFM and DFM were then used to set up appropri-
ate integrals to calculate the per cent of absorbed dose as a
function of time post administration. Estimates were then
made as to the absorbed dose for red marrow that would be
delivered by each form of the antibody (IgG, TFM and
DFM) in humans when labelled with 'Y. The monkey data
showed that at early times all of the administered activity
was in the blood circulation and this was taken to be the case
for humans. Calculations were made based on the assump-
tions that the pharmacokinetics of "'In- and 'Y-labelled
antibodies are the same as each other and the same in
monkeys and humans, also that there is no specific uptake of
radiolabelled antibodies in the marrow so that the radio-
activity in the blood and marrow are the same after a few
(<5) h. To generate numbers representative of humans the
following data for standard man were used: a total blood
volume of 5000ml; marrow spaces, absorbed fractions for
'Y P-particles and the thickness of the endosteal layer were
taken from Whitwell and Spiers (1976). Owing to the high
energy of the 90Y P-particles, the radiation absorbed doses in
the marrow and the endosteal layer are for all practical
purposes the same.
Results
Cloning ofA33 variable region genes
DNA sequences encoding the light and heavy chain variable
domains were amplified by PCR from cDNA prepared from
mRNA isolated from the A33 hybridoma and cloned into
vectors allowing expression as a chimeric IgG1. Direct bind-
ing assays were performed on culture supernatants following
transient co-expression of the heavy and light chains. The
antigen recognised by A33 is poorly characterised and has
not been isolated, so all binding assays used a human colo-
rectal tumour cell line. The results of these binding assays
showed that the chimeric antibody bound to cells expressing
the antigen as well as murine A33 (data not shown),
confirming that the cloned genes correspond to those ofA33.
Figure 2 shows the amino acid sequences of the heavy and
light chains deduced from the DNA sequence of the cloned
variable domain genes. N-terminal protein sequencing of the
first 11 amino acids gave results completely consistent with
these deduced amino acid sequences for both heavy and light
chains, confirming the appropriate genes had been cloned.
Humanisation ofA33
The 'y-I isotype was chosen for the humanised heavy chain
because this isotype best matches the murine -y-2a of the
parent antibody. Antibodies with either human -y-1 or murine
y-2a heavy chains are able to fix complement (CDC) and
mediate cellular cytotoxicity (ADCC) via interaction with
FcRI on phagocytic mononuclear cells (Burton and Woof,
1992).1 1 1 21 31
DIVMTQSQKF MSTSVGDRVS ITCKASQNVR TVVAWYQOKP
hA33 DIQMTQSPSS LSVSVGDRVT ITCKASONVR TVVAWYQQKP
41 51 61 71
mA33 GQSPKTLIYL ASNRHTGVPD RFTGSGSGTD FTLTISNVQS
hA33 GLAPKILIYLASNRHTGVPS RFSGSGSGTD FTFTISSLQP
81 91 101 108
mA33 EDLADYFCLQHWSYPLTFGS GTKLEVKR
hA33 EDIATYEOQQ HWSYPLTFGQ GTKVEVKR
b
1 11 21 31
mA33 EVKLVESGGG LVKPGGSLKL SCAASGFAFS TYDMSWVRQT
hA33 EVQLLESGGG LVQPGGSLRL SCAASGFAFS TYDMSWVRQA
41 51 52a 59 60 70
mA33 PEKRLEWVAT ISSGGSYTYY LDSVKGRFTI SRDSARNTLY
hA33 PGKGLEWVAT ISSGGSYTYY LDSVKGRFTI SRISKNTIY
80 82a-82c 86 87 97 107 113
mA33 LQMSSLRSED TALYYCAPr VVPFAYWGQG TLVTVSA
hA33 LQMNQLQAED SAIYYCAPTT VVPFAYWGQG TLVTVSS
Figure 2 Amino acid sequences of the light (a) and heavy (b)
chain variable domains of the murine and humanised A33
antibodies. The sequence of the mouse antibody as deduced from
cDNA (mA33) is shown aligned with the humanised antibody
sequence (hA33). The humanised framework sequence is derived
from the human antibody LAY (Adair et al., 1992). The three
complementarity-determining regions in each chain are under-
lined. Residues in the LAY framework that have been replaced
with mouse A33 sequence are double underlined. Numbering as
described by Kabat et al. (1987).
The murine variable regions of A33 were humanised ac-
cording to the strategy described by Adair et al. (1991). This
strategy involves using as frameworks heavy and light chains
with the greatest overall homology to the murine antibody,
and transferring into these frameworks all the residues from
the murine antibody predicted to be involved in antigen
binding. The VH of A33 shows closest homology (70%) to
the consensus sequence of human subgroup VHIII, while the
VL shows greatest homology to the consensus sequence of
human subgroups VLI and VLIV (62%). From these sub-
groups LAY, which has a VHIII heavy chain and VLI light
chain, was chosen as the human framework. Figure 2 shows
the amino acid sequences of the humanised light and heavy
chains. For the light chain residues 1-23, 35-45, 47-49,
57-86, 88 and 98-108 inclusive were derived from the LAY
sequence, (numbering as in Kabat et al., 1987) and the
residues 24-34, 46, 50-56, 87 and 89-97 inclusive were
derived from the murine sequence. Residues 24-34, 50-56
and 89-97 correspond to the complementarity determining
regions (CDRs, Kabat et al., 1987). Residues 46 and 87 are
predicted to be at the interface of the light and heavy
variable regions. Residue 46 is usually a leucine in human
antibody sequences and residue 87 is usually either a phenyl-
alanine or tyrosine.
For the heavy chain, residues 2-26, 36-49, 66-71,
74-82a, 82c-85, 87-93 and 103-113 inclusive were derived
from the LAY sequence while residues 1, 27-35, 50-65, 72,
73, 82b, 86 and 94-102 inclusive were derived from the
murine sequence. Residues 31-35, 50-65 and 95-102 in the
heavy chain correspond to the CDRs. The murine-derived
amino acids in the framework regions were included for the
following reasons. Residue 1 is usually solvent accessible and
in the vicinity of the CDR region (residues 27-30) LAY has
a residue, alanine, not normally found at this position in
human or murine VH sequences and therefore the murine
21 kDaa-
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Figure 3 SDS polyacrylamide gel of humanised A33 IgG and
TFM under non-reducing conditions. Lane 1, hA33 IgG; lane 2,
hA33 Fab'Acys; lane 3, hA33 Fab'Acys cross-linking mix; lane 4,
purified hA33 TFM.
residue was used. At positons 72 and 73 the murine residue
was used because of the predicted proximity to CDR2 and
also, in the case of residue 72, to remove the possibility of
introducing an N-linked glycosylation site into the variable
domain by the use of the LAY framework (see also Co et al.,
1991). The murine sequence was also used at the inter-
domain residue 94, where A33 has a proline, not normally
found at this position. Murine residues were used at positions
82 and 86 because the use of the human amino acids at these
positions in a humanised antibody with LAY frameworks
has previously been found to be deleterious for the expres-
sion of the heavy chain (Adair et al., 1992).
Preparation and in vitro characterisation ofhA33 IgG1 and
TFM
Small amounts of the humanised antibody were produced in
a transient expression system in CHO cells to establish that it
bound SW1222 cells expressing the antigen. Stable NSO cell
lines were then isolated to produce larger quantities of
purified material, for both hA33 IgG and Fab'Acys. The best
cell lines produced approximately 700mg 1' hA33IgGl and
500 mg 1' Fab'Acys in suspension culture.
Figure 3 shows SDS-PAGE analysis of the purified anti-
bodies under non-reducing conditions. It demonstrates that
the purified hIgG was homogeneous and fully assembled.
High-performance liquid chromatography (HPLC) analysis
also demonstrated it was free of aggregates (data not shown).
As expected the hFab'Acys was recovered largely in the form
of monovalent Fab' with little in the form of F(ab')2, consis-
tent with results for other recombinant Fab' fragments (King
et al., 1992, 1994). Cross-linking of Fab'Acys to TFM was
achieved with a yield of 60-65%, as shown by HPLC
analysis in Figure 4. SDS-PAGE analysis of the purified
TFM (Figure 3) showed a single species of approximately
150kDa under non-reducing conditions.
Figure 5 shows Scatchard analysis for the murine antibody
and hIgGI binding to SW1222 cells. These data suggest both
antibody forms have equilibrium dissociation constants (KDs)
of 1.3 nM and have approximately 300 000 sites per cell. The
antigen-binding activity of hTFM was compared with those
of monovalent hFab'Acys and hIgG in competition binding
assays in which these species were asked to compete with
murine IgG for binding to Colo2O5 cells expressing the
antigen. The results (Figure 6) demonstrate that the monova-
lent Fab' fragment binds less well than the bivalent IgG as
expected. The trivalent hTFM, on the other hand, showed
approximately 2-fold better binding than hIgG, presumably
as a result of increased avidity due to the extra antigen
binding site. This finding is consistent with results for
chimeric B72.3, for which TFM also showed 2- to 3-fold
better binding to antigen than IgG (King et al., 1994).
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Figure 6 Competitive binding assay for hA33 Fab'Acys, IgG
and TFM binding to Colo2O5 cells. hA33 IgG (A), TFM (+),
DFM (0), and Fab'Acys (-) were competed with FITC-labelled
murine A33 IgG and results (mean of triplicate determinations)
plotted as fluorescence units vs nm binding sites.
Time (min)
Figure 4 HPLC profiles at 280 nm of (a) hA33 Fab', (b) hA33
Fab' after cross-linking to TFM and (c) purified hA33 TFM.
HPLC gel filtration was carried out on a DuPont Zorbax GF-250
column run at 1 ml min'I in 0.2 M sodium phosphate buffer
pH 7.0. (a) hA33 Fab' peak has a retention time of 10.5 min with
a minor peak of F(ab')2 at 9.7 min and a buffer peak at 12.2 min.
(b) After cross-linking the major peak represents TFM at 9.0 min.
Minor peaks represent di-Fab at 9.6 min, residual monomeric
Fab' at 10.5 min, a small amount of aggregate at 8.2 min and the
same buffer peak at 12.2 min. (c) After purification the TFM
peak is still seen at 9.0 min, the only other visible peak being the
buffer peak at 12.2 min.
0)
0)
0
Bound (pM)
Figure 5 Scatchard plot of humanised A33 (A) and mouse A33
(0) binding to SW1222 cells. Experimental details as in Materials
and methods. KD values of 1.28 nm for murine A33 IgG and
1.27 nm for humanised A33 IgG were calculated from linear
regression analysis of the data points.
Biodistribution andpharmacokinetics ofhA33 IgGI, DFM and
TFM
Immunoconjugates of hIgG were prepared for 9Y labelling
by derivatisation with the 12N4-maleimide linker CT77. An
average macrocycle loading of 1.2 per molecule was achieved,
and the immunoconjugate was shown to be fully immuno-
reactive using the competition-based FACs assay both before
and after radiolabelling (data not shown). For biodistribu-
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Figure 7 Time course study showing biodistribution of 9Y-
labelled humanised A33 in nude mice bearing SW1222 tumour
xenografts. Mice were injected i.v. with 19 gCi (1O0tg) of 9Y-
labelled hA33 each. Groups of four mice were killed at 3 ( _ ),
24 (E=), 48 (EDB) and 144 h (B) post-administration and
the amount of activity was determined in tumour and normal
tissues. Each column represents the mean obtained from four
mice, error bars represent the standard deviation of the mean.
tion experiments, radiolabelling was achieved to a sp. act. of
21pCipg` with >95% incorporation of 'Y.
Figure 7 shows the biodistribution of 'Y-labelled hA33
IgG at 3, 24, 48 and 144 h in mice bearing subcutaneous
SW1222 xenografts, with tissue uptake plotted as per cent
injected dose per gram of tissue. In general, a favourable
biodistribution was achieved, with high levels of activity
localised to the tumour and little or no accumulation in any
normal tissue. The biodistribution of the humanised A33
immunoconjugate was not significantly different from that of
the murine antibody in the same xenograft system at these
time points (Antoniw et al., manuscript in preparation). For
both the murine and humanised antibodies the level of
activity localised to the tumour increased with time, even
though levels in all other tissues were falling, which led to
increasing tumour to normal tissue ratios over time (Figure
8). To assess whether this was a feature of the antibody itself
or the radioisotope used, a biodistribution experiment was
also carried out with humanised A33 labelled with 1251. In
this experiment the absolute levels of isotope retained by the
tumour were slightly lower but the tumour to blood ratios
were very, similar, suggesting that the increasing localisation
is a property of the A33 antibody rather than the nature of
the isotope/chelator system. The lower absolute levels of '251
labelled hA33 localised to the tumour are probably the result
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Figure 8 Tumour to normal tissues ratio of injected dose per
gram at different time intervals after administration. Mice bearing
SW1222 tumour xenograft were injected i.v. with either (a) 19piCi
(1O0sg) 9'Y-labelled hA33 or (b) 8gCi (10 rg) '25l-labelled hA33.
Groups of mice were killed at each time point and the amount of
activity was determined in tumour and normal tissues. Data are
expressed as the mean value with error bars denoting standard
deviation of the mean (n = 4). The value for muscle with 90Y-
labelled hA33 at 144 h is 127 ± 38. , 3 h; W, 24 h; E,
48 h; , 168 h.
of dehalogenation of the radioiodinated antibody (Brown et
al., 1987).
A series of experiments was performed to compare the
biodistribution and pharmacokinetics of hA33 IgG, DFM
and TFM. It was consistently observed that humanised TFM
and all other humanised fragments examined clear aberrantly
quickly from the circulation of mice, far more quickly than
the equivalent murine fragments. This phenomenon was
shown to be specific to mice and did not occur in rats, guinea
pigs or monkeys (data not shown). Figure 9 shows a com-
parison of biodistribution for hA33 IgG, DFM and TFM in
guinea pigs. It demonstrates the more rapid blood clearance
of the DFM and TFM, with blood activities falling to 0.01
and 0.02% i.d. g-' respectively at the 144 h time point. Blood
activity for hIgG was much higher, at 0.4% i.d. g-1, at this
time point. Figure 9 demonstrates very clearly that for DFM
much higher levels of radioactivity are taken up by the
kidney than for IgG and TFM. This high activity for the
DFM clears much more slowly from the kidney than from
the blood. At early time points kidney levels were a little
higher for TFM than IgG but much lower than for DFM,
and the activity cleared much faster from the kidney for
TFM than for DFM. These results for A33 are consistent
with the view that the kidney is the major organ of clearance
for TFM.
The pharmacokinetics of hA33 IgG, TFM and DFM were
compared in cynomolgus monkeys. Owing to safety con-
siderations, these components were labelled with "'In rather
A33 and A33 TFM conjugates forradiommunotherapy
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than 9Y, previous work having suggested that 9Y-labelled
IgG and fragments show pharmacokinetics and biodistribu-
tion very similar to those labelled with "'In (data not
shown). The plasma clearance profiles are shown in Figure
10 with the alpha and beta phase half-life values in Table I.
As expected from pharmacokinetic data in mice and guinea
pigs both TFM and DFM cleared faster from the circulation
than IgG. In addition, DFM cleared more quickly than
TFM. When plasma clearance was examined without decay
correction for the isotope (Table II) the data was most
consistent with monophasic kinetics for IgG and TFM, with
biphasic kinetics for DFM. Dosimetric calculations based on
these data suggest that when labelled with 9'Y at equivalent
amounts of radioactivity injected, the DFM would give
approximately a 5-fold lower absorbed dose to the bone
marrow than IgG, while TFM would give a 2-fold lower
absorbed dose (Table II).
Discussion
In general, the antibodies directed to tumour-associated
antigens that are currently available have been produced
from rodent hybridomas and are immunogenic in man. This
has been a major obstacle to radioimmunotherapy, since
although the first doses of some immunoconjugates have
given promising biodistribution and partial therapeutic res-
ponses, subsequent doses have been rendered ineffective by
rapid clearance due to the HAMA response elicited (Welt et
al., 1990; Mountain and Adair, 1992).
We constructed the humanised variant of A33 by substi-
tuting into the frameworks of the human antibody LAY all
the residues of the murine antibody, which we predict may
contribute to antigen binding. These residues comprise the
CDRs together with two residues on the light chain and five
on the heavy chain which may contribute to the precise
positioning of the CDRs for antigen binding (Adair et al.,
1991). Scatchard analysis suggested the murine and human-
ised variants of the antibody have equivalent affinity for the
antigen on the surface of colorectal tumour cells.
As yet there are still few data concerning the effectiveness
of full humanisation in overcoming the patient immune res-
ponse to rodent antibodies. In three reports on the immuno-
genicity of humanised antibodies in monkeys (Hakimi et al.,
1991; Singer et al., 1993; Stephens et al., 1994) the immune
response was much reduced compared with the parent
murine antibodies. In each case, an anti-idiotype response
(i.e. directed to the CDRs) developed on repeat dosing. In
the case studied in greatest detail (Stephens et al., 1994) the
CDRs appear less immunogenic when presented in the
human framework since the anti-idiotype response to the
humanised antibody was greatly reduced compared with the
anti-idiotype component of the immune response to the
murine antibody. As yet there are only three reports on the
administration of fully humanised antibodies to patients.
Two of these studies concerned the humanised antibody
CAMPATH-1H. Two non-Hodgkin lymphoma patients
treated with 1-20mg doses of this antibody for up to 43
days showed no anti-CAMPATH-lH response during the
course of treatment (Hale et al., 1988). These results should
not be over-interpreted, however, because such patients are
somewhat immunocompromised before treatment and be-
cause the treatment itself is likely to be immunosuppressive.
More recently, however, results have become available for
eight rheumatoid arthritis patients repeatedly administered
with 4-8 mg doses of CAMPATH-1H over 10 days (Isaacs
et al., 1992). Significant clinical benefit was seen in seven of
the patients, and anti-CAMPATH-IH antibodies were not
detectable in any of the patients after this one course of
treatment. Of four patients given a second course of treat-
ment, three showed a detectable anti-CAMPATH-IH res-
ponse. No data are yet available concerning the nature of
this response, whether it interferes with efficacy, and if so,
whether such interference can be overcome using larger
doses. The immune response to the humanised anti-tumourA33 and A33 TFM conjugates for radiommunotherapy
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Figure 9 Biodistribution of 9 jzCi (8 jig) 9*Y-labelled hA33 IgG ( _ ), 13 jiCi (10 jig) 9°Y-hA33 TFM ( ) and 14 ILCi (10ILg)
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percentage injected dose per gram of tissue with error bars denoting the standard deviation (n = 4). The value for DFM in the
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Figure 10 Pharmacokinetic profiles of "'In-labelled hA33 IgG
(l), TFM (0) and DFM (A) in cynomolgus monkeys. Data
were corrected for decay and plotted as mean percentage injected
dose remaining at each time point.
necrosis factor antibody CDP571 has been examined after
administration of single doses of 0.1-10 mg kg-' to human
volunteers (Stephens et al., 1994). Administration of the
lower doses led to the development of a weak anti-idiotype
response, predominantly of the IgM isotype. Anti-CDP571
antibodies were very low or undetectable after administration
of the higher doses. The limited clinical data available for
fully humanised antibodies therefore suggest they will show
substantially longer half-lives and greatly reduced immuno-
genicity compared with murine antibodies.
As described previously (Harrison et al., 1991) the 12N4
macrocycle gives extremely stable chelation of 9Y, with no
significant escape of the isotope in vivo. The potential
TableI Meanplasmaclearancehalf-lifevalues for "'In-labelled hA33
IgG, TFM and DFM in groups of two cynomolgus monkeys (decay
corrected)
Antibodyform t)I2(h) t1/2P (h)
IgG 15.8 129.0
TFM 12.8 53.7
DFM 10.8 42.0
Values were obtained using a two-compartment model (SIPHAR).
Table II Pharmacokinetics of "'In-labelled hA33 IgG, TFM and
DFM in cynomolgus monkeys
Absorbed dose to red
Effective half-life marrow andendosteum
Antibodyform (h) (radmCi-')
IgG 40.5 12.0
TFM 21.9 6.3
DFM 4.7a/23.6p 2.6
Values for effective half-life and estimates of absorbed dose in red
marrow and endosteum in man for 9Y-labelled antibodies were
determined as described in Materials and methods.
immunogenicity of the macrocycle, however, as well as that
of the humanised antibody carrier is a significant issue. It is
far from clear whether macrocyclic chelators are likely to be
immunogenic in patients. Kosmas et al. (1992) reported the
rapid development of an anti-macrocycle immune response in
ovarian cancer patients administered with antibody con-
jugates carrying 9Y or "'In in the macrocycle p-nitrobenzyl-
DOTA. Curiously, administration conditions favouring
immunogenicity (i.p. injection of relatively large doses with a
high proportion of aggregates) led to a stronger immune
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response to the macrocycle than to the antibody carrier, and
some of these patients manifested symptoms of serum sick-
ness.
More recently Watanabe et al. (1994) have examined the
immunogenicity of a similar chelator in rabbits, and con-
cluded that an anti-macrocycle response develops in animals
injected with the macrocycle conjugated to immunogenic car-
rier proteins such as murine antibodies, but not in those
injected with rabbit antibody conjugates. Studies by Kosmas
et al. (1992) to characterise the anti-macrocycle response in
patients concluded that it is predominantly directed to the
DOTA ring structure itself rather than to the linker, which
contains an aromatic ring. We have conducted a study to
examine the immunogenicity of the 12N4 macrocycle in mice.
The only major difference between the chelator used in these
studies and that used by Kosmas et al. (1992) is the presence
of the aromatic ring on the latter. The results (TS Baker et
al., manuscript in preparation) were similar to those of
Watanabe et al. (1994), in that no anti-macrocycle response
could be detected in mice injected with the macrocycle con-
jugated to a mouse antibody even using conditions very
favourable to effective immunisation. Mice injected with the
macrocycle conjugated to an immunogenic protein such as a
chimeric antibody developed an immune response with com-
ponents directed to both the carrier protein and the macro-
cycle. We conclude it is unlikely that immunogenicity of the
12N4 macrocycle will prove to limit the effectiveness of
humanised antibodies carrying 9Y administered at reason-
able doses intravenously.
Uptake of the 9Y-labelled humanised antibody by human
colorectal xenografts in nude mice was similar to that
reported for murine A33 labelled with 9Y via the same
methodology (P Antoniw et al., manuscript in preparation).
This high tumour uptake augurs well for the prospects of
achieving therapeutically effective radiation doses in colorec-
tal cancer patients. 9Y continued to accumulate in the
tumour for the humanised antibody throughout the 144 h
after injection over which measurements were made. This
continued accumulation was also observed for hA33 with
both of the other colorectal tumour cell lines studied (P
Antoniw et al., unpublished). hA33 labelled with 1251 shows
less accumulation, and the increased retention of 9Y by the
tumour cells may result from the inability of the macrocyclic
chelator to egress from the cells after internalisation.
Clinical studies with chimeric and humanised antibodies
have also suggested that these antibodies have a substantially
longer circulating half-life than murine antibodies. Humani-
sed antibodies for radioimmunotherapy may therefore deliver
an increased dose to the bone marrow from the circulating
conjugate, which would give decreased therapeutic ratios
unless tumour uptake is correspondingly increased. The pro-
duction of TFM is an attempt to circumvent this problem.
The binding avidity of TFM is increased compared with IgG
and pharmacokinetic studies show faster blood clearance in
both guinea pigs and cynomolgus monkeys. The mean beta-
phase half-life of the IgGI in cynomolgus monkeys (129 h) is
in the range previously observed for humanised antibodies in
this species (Hakimi et al., 1991; Singer et al., 1993; Stephens
et al., 1994). The mean beta-phase half-life for TFM in
cynomolgus monkeys (53.7 h) is less than half that of IgG,
and dosimetric calculations indicate that for an equivalent
injected dose of 9Y this shorter half-life would give an
approximately 2-fold benefit for TFM in terms of the radia-
tion dose to the bone marrow. Since the latter is usually the
dose-limiting toxicity in clinical studies with therapeutic
radioimmunoconjugates, it is likely TFM would allow a
higher maximum tolerated dose.
Unlike all other antibody fragments carrying metallic iso-
topes which have been examined (see for example Sharkey et
al., 1990) the TFM does not lead to high-level accumulation
of the isotope in the kidney or other non-specific tissues. In
the present studies DFM showed faster blood clearance and
projected bone marrow doses lower than those for both IgG
and TFM, but is clearly not an acceptable vehicle for deliver-
ing 9Y because it leads to unacceptably high accumulation of
this isotope in the kidney. Such kidney accumulation does
not occur for DFM labelled with radioiodine (data not
shown), and it is likely that the DFM is the most appropriate
delivery vehicle for therapy with '3'I.
Clinical success with radioimmunotherapy has so far large-
ly been restricted to haematological malignancies such as
lymphomas and leukaemias. hA33 TFM carrying 9Y in the
12N4 macrocycle represents one of the first attempts to
optimise all components of a radioimmunoconjugate for
treatment of solid tumours. Evaluation of this second genera-
tion immunoconjugate in colorectal cancer patients may
reveal new potential for radioimmunotherapy of solid
tumours. As the first stage in clinical evaluation of this
technology, a quantitative biodistribution study in colorectal
cancer patients using hA33 TFM carrying "'In is in pro-
gress.
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